About Us

Our vision is to redefine the treatment for ocular disease by developing multi-targeting drugs for early intervention in both corneal and retinal diseases.

Current treatments do not sufficiently target the complex pathologies in many progressive eye diseases and are often provided too late leaving many patients to experience irreversible vision loss.

Developed as an easy-to-apply eye drop, our therapies will combine broad efficacy with safe early treatment in the aim to reach large patient groups.

Leadership

We are an experienced team of drug developers spanning preclinical translation through all phases of clinical development to drug approvals across a wide range of indication areas including ophthalmology.

Per Gjorstrup, MD PhD

President, and Chief Executive Officer

Per Gjorstrup, MD PhD

Per Gjorstrup, MD PhD

President, and Chief Executive Officer

Dr. Per Gjorstrup is the Founder of Anida Pharma and has a long career in the pharmaceutical and biotechnology industry. Primarily focusing on translational science, under his leadership 7 first-in-class therapies have been brought into clinical development with a focus on inflammation and oncology and some in continued development to approval including the first bi-specific antibody construct Blincyto for the treatment of leukemia, and earlier Amevive for treatment of psoriasis, and Immunosorba for the treatment of antibody related conditions.

His preclinical and clinical drug development experience in ophthalmology covers both anterior and posterior segment indications. Per has published more than 60 scientific papers in leading journals and is named author on several patents. Previous senior management positions include at Resolvyx Pharmaceuticals, also co-founder, Micromet, Biogen, Pharmacia (later Pfizer) and Astra (now AstraZeneca). He received his MD and PhD degrees from the University of Lund, Sweden, and previously held adjunct appointments at Lund University, Harvard Medical School and SUNY College of Optometry.


Raymond E. Dagger, PhD

Chemistry and formulation

Raymond E. Dagger, PhD

Raymond E. Dagger, PhD

Chemistry and formulation

Dr. Raymond Dagger has a career that spans 45+ years in CMC Active Pharmaceutical Ingredient development with SmithKline Beecham (now GSK), Eisai Research Institute, Cardinal Health Pharmaceutical Technologies and Services (now Catalent), Sequoia Pharmaceuticals, PPD Consulting and Stonehedge Pharmaceutical Consulting, LLC.
During that time, he has been part of the teams that have brought 12+ molecules through regulatory approval. He has contributed to the development of an additional 20+ molecules through earlier stages of development. He has extensive experience with the development of long, complex syntheses of drug candidates, including Lipid A mimics, Natural Products including Resolvin derivatives.

He received a B.A in Biochemistry from Temple University, an M.A. in Organic Chemistry from Temple University, and a Ph.D. in Synthetic Organic Chemistry from Bryn Mawr College under the direction of Dr. Charles Swindell.


John Kapeghian, PhD

Preclinical Development

John Kapeghian, PhD

John Kapeghian, PhD

Preclinical Development

John Kapeghian is a board certified toxicologist with over 35 years of experience in preclinical safety. He obtained his Ph.D. in pharmacology/toxicology at the University of Mississippi, worked as a senior scientist, and lead the experimental toxicology group at Ciba Pharmaceuticals, now Novartis, before taking a position as Director of Operations and VP of Regulatory Consulting at Sierra Biomedical, a primate research facility in Nevada. Sierra then became Charles River Preclinical Services, where John started and ran the Navigator Advisory Services group. John started his own consulting company in 2006, and has drafted several INDs and regulatory dossiers for multinational Pharma and Biotech companies.

He also sponsored and conducted several Study Director training workshops for CROs and Pharma toxicologists. John recently joined Frontage Laboratories as Sr. VP of Global Safety & Toxicology and is currently directing toxicology operations at the Experimur site in Chicago.


Ulrich Granzer, PhD

Regulatory affairs

Ulrich Granzer, PhD

Ulrich Granzer, PhD

Regulatory affairs

Independent consultant, owner and CEO of Granzer Regulatory Consulting & Services with currently 50 employees. Granzer is focusing on global drug development and regulatory affairs with special considerations for orphan drugs. Ulrich Granzer has major experience with biotech products (proteins, cell-based therapies, gene therapies, oligonucleotides) and small molecules. A mainstay of his work is dedicated to orphan drugs.

He holds a PhD in pharmaceutical chemistry. Prior to being independent he held senior positions at Glaxo, BASF pharma Knoll, and Bayer.
He has a track record of working on more than 300 new molecular entities (small molecules, proteins incl. antibodies, oligonucleotides, gene therapies, cell therapies). Recently he and his firm supported the first approval of a mRNA vaccine against Covid 19.